Stoke Therapeutics
STOK
105 hedge funds and large institutions have $533M invested in Stoke Therapeutics in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 34 increasing their positions, 30 reducing their positions, and 7 closing their positions.
186% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 7
14% more funds holding
Funds holding: 92 → 105 (+13)
13% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 30
4% less capital invested
Capital invested by funds: $556M → $533M (-$22.7M)
2.67% less ownership
Funds ownership: 109.91% → 107.24% (-2.7%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
94% less call options, than puts
Call options by funds: $308K | Put options by funds: $5.57M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$14.2M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$5.89M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.47M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.51M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$18.4M |
| 2 |
CAC
Cowen and Company
New York
|
-$11.8M |
| 3 |
Millennium Management
New York
|
-$4.68M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.89M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.29M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BHWM
101
Beaird Harris Wealth Management
Dallas,
Texas
| $1K | – | – | – |
|
102
First Manhattan
New York
| $1K | – | – | – |
|
|
IRC
103
Investors Research Corp
Atlanta,
Georgia
| $1K | – | – | – |
|
|
104
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$3.29M | -249,364 | Closed |
|
|
BFM
105
Boothbay Fund Management
New York
| – | -$3.27M | -205,463 | Closed |
|
|
ABG
106
Ally Bridge Group
New York
| – | -$2.31M | -175,000 | Closed |
|
|
AC
107
Amitell Capital
Singapore
| – | -$856K | -64,807 | Closed |
|
|
ACM
108
Altium Capital Management
New York
| – | -$634K | -48,000 | Closed |
|
109
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$359K | -27,158 | Closed |
|
110
Group One Trading
Chicago,
Illinois
| – | -$3.19K | -200 | Closed |
|
|
LC
111
Lindbrook Capital
Calabasas,
California
| – | +$64 | +4 | New |
|
STOK Hedge Fund Activity: Q3 2022 in Review
105 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q3 2022, worth a combined $533M — down 4.1% from $556M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new STOK positions and 7 closed out — a net gain of 13 holders — while 34 added to existing stakes and 30 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $14.2M. The largest seller was Redmile Group, cutting an estimated $18.4M.
- 105 institutional investors held Stoke Therapeutics (STOK) as of Q3 2022, up from 92 in Q2 2022.
- Funds reported $533M of Stoke Therapeutics stock for Q3 2022, down 4.1% quarter-over-quarter.
- 20 funds opened new Stoke Therapeutics positions in Q3 2022 and 7 closed out, a net change of +13 holders.
- The largest Stoke Therapeutics buyer in Q3 2022 was Avidity Partners Management, an estimated $14.2M added.
- The largest Stoke Therapeutics seller in Q3 2022 was Redmile Group, an estimated $18.4M sold.
Based on aggregated 13F filings for Q3 2022.